NASDAQ:RAIN
Delisted
Rain Therapeutics Inc. Stock News
$1.21
+0 (+0%)
At Close: Apr 24, 2024
Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Virtual Conference
08:00am, Monday, 14'th Nov 2022
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead produc
Rain Therapeutics Inc. (RAIN) Q3 2022 Earnings Call Transcript
10:43pm, Saturday, 12'th Nov 2022
Rain Therapeutics Inc. (NASDAQ:RAIN ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Dan Ferry – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Rob
Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022
08:00am, Thursday, 27'th Oct 2022
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead produ
Rain Therapeutics Inc.'s (RAIN) CEO Avanish Vellanki on Q2 2022 Results - Earnings Call Transcript
10:49am, Saturday, 06'th Aug 2022
Rain Therapeutics Inc. (NASDAQ:RAIN ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Bob Yedid – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Nelson
Rain Therapeutics to Report Second Quarter 2022 Financial Results and Highlights of Recent Progress on August 4, 2022
08:00am, Thursday, 21'st Jul 2022
NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report
Rain Therapeutics Inc. (RAIN) CEO Avanish Vellanki on Q1 2022 Results - Earnings Call Transcript
08:11pm, Saturday, 07'th May 2022
Rain Therapeutics Inc. (NASDAQ:RAIN ) Q1 2022 Results Conference Call May 4, 2022 5:00 PM ET Company Participants Bob Yedid - LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - Chief Scientific
Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Recent Progress on May 4, 2022
08:00am, Wednesday, 20'th Apr 2022
NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will repor
Rain Therapeutics, Inc. (RAIN) CEO Avanish Vellanki on Q4 2021 Results - Earnings Call Transcript
10:48am, Friday, 04'th Mar 2022
Rain Therapeutics, Inc. (RAIN) CEO Avanish Vellanki on Q4 2021 Results - Earnings Call Transcript
Digital PCR (dPCR) and Real-Time PCR (qPCR) Market Worth USD 1180.1 million, Globally, by 2028 at 6.8% CAGR - Exclusive Report by Absolute Reports
06:37am, Friday, 18'th Feb 2022 Benzinga
Pune, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Global Digital PCR (dPCR) and Real-Time PCR (qPCR) Market report delivers a complete overview of key components like drivers, limitations, historic and current trends, technical development, and future growth. Research report contains company analysis, size, share, revenue and sales of the company, current advancements. Digital PCR and Real-Time PCR market analysis also focuses on the global key top industry players in the market, with details such as company profiles, capacity, production, price, cost, revenue. Get a Sample Copy of the Report at - https://www.absolutereports.com/enquiry/request-sample/20190575 The global Digital PCR and Real-Time PCR market size is projected to reach USD 1879.8 million by 2028, from USD 1180.1 million in 2021, at a CAGR of 6.8% during 2022-2028. Polymerase chain reaction (PCR) is a laboratory technique performed commonly to amplify DNA, thereby producing many copies of a particular section of DNA in interest.
AmerisourceBergen Debuts RFID Tagging Service, Allowing Customers Nationwide To Purchase Pre-Tagged Product That Is Also Technology Agnostic
01:30pm, Tuesday, 14'th Dec 2021 Kwhen FinanceRain Therapeutics to Present at Upcoming Investor Conferences
10:05am, Monday, 22'nd Nov 2021
NEWARK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish V
Rain Therapeutics, Inc. (RAIN) CEO Avanish Vellanki on Q3 2021 Results - Earnings Call Transcript
07:25pm, Wednesday, 10'th Nov 2021
Rain Therapeutics, Inc. (RAIN) CEO Avanish Vellanki on Q3 2021 Results - Earnings Call Transcript
Presentations highlight potential of the oral MDM2 inhibitor, milademetan, in advanced cancers with MDM2 amplification, GATA3 mutant ER-positive breast cancer, and Merkel cell carcinoma Presentations
Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
08:00am, Wednesday, 22'nd Sep 2021
NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish
Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
08:00am, Thursday, 09'th Sep 2021
NEWARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish V